ADC Therapeutics to Present Innovations at Upcoming Investor Conferences
ADC Therapeutics SA (NYSE: ADCT), a leading global player in the field of antibody drug conjugates (ADCs), is gearing up to connect with investors at two major conferences next month. These presentations, highlighting their groundbreaking work, offer a valuable chance for stakeholders to learn about the future of cancer treatment.
Participation in Key Events
At the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, Ameet Mallik, the Chief Executive Officer of ADC Therapeutics, will discuss the company’s recent advancements and strategic direction. This virtual fireside chat is scheduled to start at 7:00 a.m. ET.
Additionally, ADC Therapeutics will participate in the 10th Cantor Global Healthcare Conference on September 18, 2024, from 11:30 a.m. to 12:00 p.m. ET. During this session, Mallik will share further insights into the promising developments at ADC Therapeutics.
How to Access Presentations
Investors can tune in to live webcasts of both presentations by visiting the Events & Presentations page in the Investors section of the ADC Therapeutics website. Each presentation will also be available for replay for about 30 days after the events, ensuring that anyone interested can access the shared information.
Innovations at ADC Therapeutics
ADC Therapeutics is leading the way in treating hematologic malignancies and solid tumors. Their flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from European regulators. This treatment is particularly important for patients who have relapsed or have refractory diffuse large B-cell lymphoma after multiple lines of therapy.
Beyond ZYNLONTA, the company is actively working on several other ADCs, further expanding its portfolio and bolstering its contributions to oncology.
Company Overview
Headquartered in Lausanne, Switzerland, with operations in London and New Jersey, ADC Therapeutics is dedicated to transforming cancer care through innovation and expertise in ADC technology. Their ongoing commitment is clear as they progress through clinical and preclinical phases for a variety of ADC candidates.
Contact Information
For investment inquiries, please reach out to Marcy Graham at ADC Therapeutics via email at Marcy.Graham@adctherapeutics.com or by phone at +1 650-667-6450.
For media inquiries, contact Nicole Riley at Nicole.Riley@adctherapeutics.com or call +1 862-926-9040.
Frequently Asked Questions
What is the focus of ADC Therapeutics?
ADC Therapeutics specializes in developing antibody drug conjugates aimed at treating various cancers, particularly making significant advancements in hematologic malignancies.
When are the investor conferences scheduled?
The H.C. Wainwright conference is set for September 9, 2024, followed by the Cantor Global Healthcare Conference on September 18, 2024.
How can I access the presentations?
You can find live webcasts of the presentations on the ADC Therapeutics website in the Events & Presentations section, with replays available for 30 days afterward.
Who will be leading the presentations?
Ameet Mallik, the Chief Executive Officer of ADC Therapeutics, will lead the discussions at both conferences.
What is ZYNLONTA?
ZYNLONTA is an innovative treatment developed by ADC Therapeutics for relapsed or refractory diffuse large B-cell lymphoma, which has received accelerated approval from the FDA.
